Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Structure and function in gene patenting

Nature Genetics volume 15, pages 125–130 (1997)Cite this article

Abstract

The United States patent system treats DNA sequences as large chemical compounds in determining their patentability. This approach has been helpful to those who seek to patent previously unidentified DNA sequences, but it may prove less advantageous from the perspective of those who elucidate biological functions and disease relevance of previously identified genes. A current controversy over patent rights for DNA sequences encoding leptin receptors provides a useful case study for illustrating some of the issues that are likely to arise in applying doctrine derived from chemical patent cases in the context of gene discovery.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 927 F.2d 1200 (Fed. Cir.), cert. denied sub nom. Genetics Institute v. Amgen, 502 U.S. 856 (1991).

  2. In re Papesch, 315 F.2d 381 (CCPA 1963).

  3. U.S. Patent Act. 35 U.S. Code § 103(a).

  4. Final act embodying the results of the uruguay round of multilateral trade negotiations, Apr. 15, 1994, Annex IC: Agreement on Trade-Related Aspects of Intellectual Property Rights §§ 27–34, 33I.LM.81, reprinted in The Results of the Uruguay Round of Multilateral Trade Negotiations—The Legal Texts (ed. GATT Secretariat)1–19, 365–403 (1994).

  5. Convention on the Grant of European Patents § 53, opened for signature October 5, 13 I.LM.290 (1973).

  6. Dickson, D. Europe tries to untangle laws on patenting life. Science 243, 1002–1003 (1989).

    Article  CAS  Google Scholar 

  7. Kass, L.R., Patenting Life. Commentary at p.56.(December, 1981).

  8. Dresser, R. Ethical and legal issues in patenting new animal life. Jurimet. J. 28, 399–435 (1988).

    Google Scholar 

  9. 35 U.S. Code § 101.

  10. 35 U.S. Code § 102.

  11. 35 U.S. Code §§ 101, 112.

  12. 35 U.S. Code § 103.

  13. 35 U.S. Code § 112.

  14. Funk Bros. Seed Co. v. Kalo Inoculant Co., 33 U.S. 127 (1948).

  15. Amgen Inc. v. Chugai Pharmaceutical Co., 13 USPQ2d (BNA) 1737,1759 (D. Mass. (1989).

  16. Diamond v. Chakrabarty, 447 U.S. 303 (1980).

  17. Parke-Davis & Co. v. H.K. Mulford & Co., 189 F. 95 (S.D.N.Y. 1911).

  18. Kuehmsted v. Farbenfabriken, 179 F. 701 (7th Cir. 1910), cert. denied, 220 U.S. 622 (1911).

  19. Merck & Co. v. Olin Mathieson Corp., 253 F.2d 156 (4th Cir. (1958).

  20. In re Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970).

  21. In re Deuel. 51 F.3d 1552 (Fed. Cir. 1995).

  22. In re Bell. 991 F.2d 781 (Fed. Cir. 1993).

  23. Brenner v. Manson, 383 U.S. 519 (1966).

  24. Eisenberg, R & Merges, R. Opinion letter as to the patentability of certain inventions associated with the identification of partial cDNA sequences. Amer. Intell. Prop. L. Ass'n Q. J. 23, 1–52 (1995).

    Google Scholar 

  25. U.S. Pat & Trademark Off. PTO Utility examination guidelines Fed. Reg. 60, 36,263 (1995).

  26. In re Spada, 911 F.2d 705 (Fed. Cir. 1990).

  27. In re Thuau, 135 F.2d 344 (CCPA 1943).

  28. In re May, 574 F.2d 1082 (CCPA 1978).

  29. U.S. Patent No. 4,724,232 (Feb. 9, 1988).

  30. U.S. Patent No. 4,833,130 (May 23, 1989).

  31. U.S. Patent No. 4,837,208 (June 6, 1989).

  32. U.S. Patent No. 4,818,750 (Apr. 4, 1989).

  33. U.S. Patent No. 4,828,838 (May 9, 1989).

  34. U.S. Patent No. 4,818,538 (Apr. 4, 1989).

  35. Ex parte Novitski. 26 USPQ2d (BNA) 1389 (Bd. Pat. App. & Interf. 1993).

  36. In re Hoch, 428 F.2d 1341 (1970).

  37. 919 F.2d 688 (Fed. Cir. 1990), cert denied sub nom. Dillon v. Manbeck. 500 U.S. 904 (1991).

  38. 566 F.2d 81,195 USPQ (BNA) 753 (CCPA 1977).

  39. Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–431 (1994).

    Article  CAS  Google Scholar 

  40. Hamilton, J. et al. Is this ‘fat gene’ worth its fat tab? Business Week (March 20, 1995).

  41. Lonnqvist, F., Amer, P., Norfors, L & Schalling, M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nature Med. 1, 950–953 (1995).

    Article  CAS  Google Scholar 

  42. Hamilton, B.S., Paglia, D., Kwan, A.T.M. & Deitel, M. Increased obese mRNA expression in developmental fat cells from massively obese humans. Nature Med. 1, 953–956 (1995).

    Article  CAS  Google Scholar 

  43. Maffei, M. et al. Leptin levels in human and rodent: measurement of plasma leptin and OB RNA in obese and weight reduced subjects. Nature Med. 1, 1155–1161 (1995).

    Article  CAS  Google Scholar 

  44. Considine, R.V. et al. Serum immunoreactive-leptin concentrations in normalweight and obese humans. New Engl. J. Med. 334, 292–295 (1996).

    Article  CAS  Google Scholar 

  45. Tartaglia, L.A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263–71 (1995).

    Article  CAS  Google Scholar 

  46. Millennium Pharmaceuticals, Inc, Common Stock Prospectus at p.11 (May 6, 1996).

  47. Progenitor, Inc., Progenitor announces publication of patent application for leptin receptor (Press Release, March 22, 1996).

  48. Patent Cooperation Treaty June 19, 1970, 28U.S.T.7645, as amended, Art 21.

  49. Progenitor, Inc., International Patent Application No. WO 96/08510 (March, 21 1996).

  50. Cioffi, J.A. et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nature Med. 2, 585–589 (1996).

    Article  CAS  Google Scholar 

  51. Chen, H. et al. Evidence that the diabetes gene encodes the leptin receptor identification of a mutation in the leptin receptor gene in db/db mice. Cell 84. 491–495 (1996).

    Article  CAS  Google Scholar 

  52. Lee, G-H. et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632–635 (1996).

    Article  CAS  Google Scholar 

  53. Vaisse, C. et al. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nature Genet 14, 85–96 (1996).

    Article  Google Scholar 

  54. Progenitor, Inc., Common stock prospectus (subject to completion, dated July 11, 1996).

  55. Reuters Financial Service. Progenitor Inc. postpones IPO, cites market (Aug. 30, 1996) (available in LEXIS, News Library, Wires File).

  56. Business Wire. Amgen and Progenitor sign leptin receptor agreement (6) (available in LEXIS, News Library, Wires File).

  57. Sherwood, P. Owning genes vs. cloning genes. Bioventure View 15–16 (June, 1996).

  58. 29 F.3d 1555 (1994).

  59. Greer, T.J. Jr Writing and Understanding U.S. Patent Claims (Michie, Charlottesville, VA, 1979).

  60. U.S. Pat No. 5,506,133 (Apr. 9, 1996).

  61. U.S. Pat. No. 5,504,003 (Apr. 2, 1996).

  62. U.S. Pat No. 5.501,969 (Mar. 26, 1996).

  63. Goldstein, J. & McConathy. E. Patent applications on partial cDNA sequences. J. NIH Res. 7, 58–61 (1995).

    Google Scholar 

  64. Steffe, E. & Covert, J. Expressed sequence tags: any prior art effect? Biotechnol. Law Report 14, 947–952 (1995).

    Article  Google Scholar 

  65. In re Hack, 245 F.2d 246,248 (CCPA 1957).

Download references

Author information

Authors and Affiliations

  1. University of Michigan Law School, Hutchins Hall, Ann Arbor, Michigan, 48104, USA

    Rebecca S. Eisenberg

Authors
  1. Rebecca S. Eisenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eisenberg, R. Structure and function in gene patenting. Nat Genet 15, 125–130 (1997). https://doi.org/10.1038/ng0297-125

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0297-125

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing